Herrmann N, et al. - Researchers performed this 14-week, randomized, double-blind, cross-over trial to compare the efficacy and safety of nabilone with placebo (6 weeks each) for agitation in patients with moderate-to-severe Alzheimer's disease. Compared with placebo, nabilone resulted in improved agitation, overall behavior, and caregiver distress but with greater sedation. Treatment-limiting sedation was not significantly different between nabilone and placebo. The investigators concluded that agitation could be treated with nabilone in this population, but recommended closely monitoring patients for sedation and cognition.